2don MSN
‘King Keytruda’s reign continues.’ Investors aren’t wowed by a promising new lung cancer drug
The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug ...
3don MSN
A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, ...
The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug Summit Therapeutics and Akeso shared more data for their experimental lung-cancer drug ...
In combination with Keytruda, the antibody-drug conjugate slowed progression compared to anti-PD-1 therapy alone.
Stocktwits on MSN
SMMT stock surges overnight: Cancer drug survival win raises the bar as PFE, BMY, MRK chase Keytruda's successor
New ASCO data boosted the case for Ivonescimab as a potential challenger to Merck's blockbuster cancer drug Keytruda. ・Phase ...
Keytruda is an immunotherapy drug that is prescribed to cancer patients and is used to treat different types of cancer. It was first approved by the FDA in 2014 for the treatment of advanced or ...
With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) and Keytruda, Merck & Co.’s partner Kelun-Biotech is the latest to claim that ...
The FDA has approved Keytruda Qlex, an injected version of a popular cancer drug that until now has only been available via infusion. The FDA approved a new injected version of the cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results